Reviewer's report

Title: A Randomized, Phase III Trial of Capecitabine plus Bevacizumab versus Capecitabine plus Irinotecan plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer: The AIO KRK 0110 Trial / ML22011 Trial

Version: 1 Date: 5 July 2011

Reviewer: Stephen Clarke

Reviewer's report:

This is a study by a major German co-operative research group. The study is principally evaluating altered dose intensity at different time points in inoperable metastatic CRC patients receiving the combination of bevacizumab and capecitabine with/without irinotecan. The study lacks novelty, but may clarify some issues in treatment of patients in this circumstance. The combination of capecitabine and irinotecan is not popular with many medical oncologists, because of toxicity concerns, however this is not explored at all in the manuscript. In fact, the rationale for the choice of this treatment over other regimens receives little attention and should be expanded.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No competing interests